Joyce M Slingerland

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon

John M.L. Ebos, Mark Clemons, Robert Buckman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.

Gordon B Mills, G. Mills, Z. Nawaz, 2007, The Journal of clinical investigation.